Immunomedics, Inc., (Nasdaq: IMMU) today announced that the Company was advised late yesterday that its abstract, “Therapy of refractory/relapsed metastatic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE